Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: Remission of refractory anemia following mycophenolate mofetil

J. T. Lin, W. S. Wang, C. C. Yen, T. J. Chiou, J. H. Liu, L. T. Hsiao, M. H. Yang, T. C. Chao, C. J. Tai, P. M. Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Autoimmune hemolytic anemia (AIHA) rarely occurs in myelodysplastic syndrome (MDS). A 36-year-old Asian female was diagnosed with MDS (refractory cytopenia with multilineage dysplasia, RCMD) and complicated by AIHA 7 months later. Secondary myelofibrosis developed at the same time. Steroid therapy was ineffective and cyclosporin A (CsA) was discontinued due to its neurotoxicity with the development of leukoencephalopathy. However, the patient achieved a good hematological response after the use of mycophenolate mofetil (MMF, CellCept) with a dose of 1 g/day and prednisolone (15 mg/day). Prednisolone was tapered off over the next 3 weeks. The patient did not require any blood support 4 weeks after the use of MMF and has been hematologically stable for 4 months. To our knowledge, this is the first report of using MMF in treating MDS complicated by AIHA. MMF might be considered as a salvage therapy for patients with refractory anemia complicated by AIHA.

Original languageEnglish
Pages (from-to)723-726
Number of pages4
JournalAnnals of Hematology
Volume81
Issue number12
DOIs
Publication statusPublished - Dec 2002
Externally publishedYes

Fingerprint

Refractory Anemia
Mycophenolic Acid
Autoimmune Hemolytic Anemia
Myelodysplastic Syndromes
Prednisolone
Leukoencephalopathies
Salvage Therapy
Primary Myelofibrosis
Cyclosporine
Steroids

Keywords

  • Autoimmune hemolytic anemia
  • Mycophenolate mofetil
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

Myelodysplastic syndrome complicated by autoimmune hemolytic anemia : Remission of refractory anemia following mycophenolate mofetil. / Lin, J. T.; Wang, W. S.; Yen, C. C.; Chiou, T. J.; Liu, J. H.; Hsiao, L. T.; Yang, M. H.; Chao, T. C.; Tai, C. J.; Chen, P. M.

In: Annals of Hematology, Vol. 81, No. 12, 12.2002, p. 723-726.

Research output: Contribution to journalArticle

Lin, J. T. ; Wang, W. S. ; Yen, C. C. ; Chiou, T. J. ; Liu, J. H. ; Hsiao, L. T. ; Yang, M. H. ; Chao, T. C. ; Tai, C. J. ; Chen, P. M. / Myelodysplastic syndrome complicated by autoimmune hemolytic anemia : Remission of refractory anemia following mycophenolate mofetil. In: Annals of Hematology. 2002 ; Vol. 81, No. 12. pp. 723-726.
@article{7706bba4e345492f9b6733f9a3181149,
title = "Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: Remission of refractory anemia following mycophenolate mofetil",
abstract = "Autoimmune hemolytic anemia (AIHA) rarely occurs in myelodysplastic syndrome (MDS). A 36-year-old Asian female was diagnosed with MDS (refractory cytopenia with multilineage dysplasia, RCMD) and complicated by AIHA 7 months later. Secondary myelofibrosis developed at the same time. Steroid therapy was ineffective and cyclosporin A (CsA) was discontinued due to its neurotoxicity with the development of leukoencephalopathy. However, the patient achieved a good hematological response after the use of mycophenolate mofetil (MMF, CellCept) with a dose of 1 g/day and prednisolone (15 mg/day). Prednisolone was tapered off over the next 3 weeks. The patient did not require any blood support 4 weeks after the use of MMF and has been hematologically stable for 4 months. To our knowledge, this is the first report of using MMF in treating MDS complicated by AIHA. MMF might be considered as a salvage therapy for patients with refractory anemia complicated by AIHA.",
keywords = "Autoimmune hemolytic anemia, Mycophenolate mofetil, Myelodysplastic syndrome",
author = "Lin, {J. T.} and Wang, {W. S.} and Yen, {C. C.} and Chiou, {T. J.} and Liu, {J. H.} and Hsiao, {L. T.} and Yang, {M. H.} and Chao, {T. C.} and Tai, {C. J.} and Chen, {P. M.}",
year = "2002",
month = "12",
doi = "10.1007/s00277-002-0539-3",
language = "English",
volume = "81",
pages = "723--726",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Myelodysplastic syndrome complicated by autoimmune hemolytic anemia

T2 - Remission of refractory anemia following mycophenolate mofetil

AU - Lin, J. T.

AU - Wang, W. S.

AU - Yen, C. C.

AU - Chiou, T. J.

AU - Liu, J. H.

AU - Hsiao, L. T.

AU - Yang, M. H.

AU - Chao, T. C.

AU - Tai, C. J.

AU - Chen, P. M.

PY - 2002/12

Y1 - 2002/12

N2 - Autoimmune hemolytic anemia (AIHA) rarely occurs in myelodysplastic syndrome (MDS). A 36-year-old Asian female was diagnosed with MDS (refractory cytopenia with multilineage dysplasia, RCMD) and complicated by AIHA 7 months later. Secondary myelofibrosis developed at the same time. Steroid therapy was ineffective and cyclosporin A (CsA) was discontinued due to its neurotoxicity with the development of leukoencephalopathy. However, the patient achieved a good hematological response after the use of mycophenolate mofetil (MMF, CellCept) with a dose of 1 g/day and prednisolone (15 mg/day). Prednisolone was tapered off over the next 3 weeks. The patient did not require any blood support 4 weeks after the use of MMF and has been hematologically stable for 4 months. To our knowledge, this is the first report of using MMF in treating MDS complicated by AIHA. MMF might be considered as a salvage therapy for patients with refractory anemia complicated by AIHA.

AB - Autoimmune hemolytic anemia (AIHA) rarely occurs in myelodysplastic syndrome (MDS). A 36-year-old Asian female was diagnosed with MDS (refractory cytopenia with multilineage dysplasia, RCMD) and complicated by AIHA 7 months later. Secondary myelofibrosis developed at the same time. Steroid therapy was ineffective and cyclosporin A (CsA) was discontinued due to its neurotoxicity with the development of leukoencephalopathy. However, the patient achieved a good hematological response after the use of mycophenolate mofetil (MMF, CellCept) with a dose of 1 g/day and prednisolone (15 mg/day). Prednisolone was tapered off over the next 3 weeks. The patient did not require any blood support 4 weeks after the use of MMF and has been hematologically stable for 4 months. To our knowledge, this is the first report of using MMF in treating MDS complicated by AIHA. MMF might be considered as a salvage therapy for patients with refractory anemia complicated by AIHA.

KW - Autoimmune hemolytic anemia

KW - Mycophenolate mofetil

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0036963441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036963441&partnerID=8YFLogxK

U2 - 10.1007/s00277-002-0539-3

DO - 10.1007/s00277-002-0539-3

M3 - Article

C2 - 12483369

AN - SCOPUS:0036963441

VL - 81

SP - 723

EP - 726

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 12

ER -